Akari Therapeutics plc (AKTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AKTX SEC filings page.
This page shows Akari Therapeutics plc (AKTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Akari remains a development-stage operation: recurring losses and cash needs are being funded mainly outside day-to-day operations.
Operating cash use eased from$12.6M in FY2024 to$10.6M in FY2025. Financing supplied$11.0M in FY2024 and$13.2M in FY2025, so reported cash requirements were met through financing rather than operations.
Research investment exceeded sales in FY2022, with
By FY2025, equity had recovered to
Financial Health Signals
Akari Therapeutics plc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Akari Therapeutics plc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Akari Therapeutics plc reported a net loss of $17.3M while operations used $10.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Akari Therapeutics plc reported an operating loss of $17.3M against $100K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Akari Therapeutics plc reported -$4.8M in net income in Q2 2026. This represents a decrease of 153.7% from the same quarter a year earlier. Against the prior quarter it is up 66.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Akari Therapeutics plc held $7.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Akari Therapeutics plc's ROE was -25.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 18.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 74.7 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Akari Therapeutics plc invested $2.1M in research and development in Q2 2026. This represents an increase of 211.4% from the same quarter a year earlier. Against the prior quarter it is up 42.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
AKTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.1M+211.4% | $1.5M+79.5% | N/A | $249K+74.1% | $667K-79.9% | $813K-64.3% | N/A | $143K-54.5% |
| SG&A Expenses | $2.5M+3.0% | $2.2M-20.0% | N/A | $2.0M+15.6% | $2.5M+9.4% | $2.7M-26.9% | N/A | $1.7M-39.4% |
| Operating Income | -$4.6M-47.5% | -$15.8M-347.0% | N/A | -$7.4M-153.0% | -$3.1M | -$3.5M+41.1% | N/A | -$2.9M-16.8% |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$2.9M |
| Interest Expense | $80K+60.0% | $61K+10.9% | N/A | $100K+44.9% | $50K-2.0% | $55K | N/A | $69K |
| Income Tax | N/A | -$859K | N/A | -$1.1M | $0 | $0 | N/A | N/A |
| Net Income | -$4.8M-153.7% | -$14.5M-290.1% | N/A | -$6.4M-121.1% | -$1.9M | -$3.7M+33.4% | N/A | -$2.9M-0.8% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00+100.0% | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Diluted Shares (Avg) | 143.32B | 118.76B+117.6% | N/A | 65.33B+167.9% | 62.94B | 54.59B | N/A | 24.39B+141.0% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
AKTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.6M-24.1% | $33.9M-33.5% | $47.9M-5.3% | $45.4M+1559.7% | $50.9M+3448.7% | $51.0M+1738.3% | $50.6M+1061.0% | $2.7M |
| Current Assets | $8.3M+152.2% | $3.6M+7.2% | $5.5M+85.0% | $2.9M+7.8% | $3.3M+147.9% | $3.3M+20.8% | $3.0M-32.0% | $2.7M |
| Cash & Equivalents | $7.7M+183.8% | $2.8M+7.2% | $5.2M | $2.5M+13.3% | $2.7M+1049.8% | $2.6M+97.1% | $0-100.0% | $2.2M-52.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | $8.4M0.0% | $8.4M | $8.4M | $8.4M | $8.4M | N/A |
| Total Liabilities | $20.0M-20.9% | $19.5M-33.2% | $19.6M-30.9% | $22.7M+140.7% | $25.3M+392.6% | $29.2M+361.9% | $28.3M+518.1% | $9.4M |
| Current Liabilities | $13.9M-18.7% | $13.4M-35.8% | $12.4M-38.0% | $15.6M+65.1% | $17.1M | $20.9M+230.5% | $19.9M+334.3% | $9.4M |
| Non-Current Liabilities | $6.1M-25.4% | $6.1M-26.6% | $7.2M-14.4% | $7.1M | $8.2M | $8.3M | $8.4M | $0 |
| Total Equity | $18.6M-27.4% | $14.4M-33.9% | $28.3M+27.4% | $22.7M+438.9% | $25.6M+791.5% | $21.7M+712.0% | $22.2M+9807.0% | -$6.7M-3242.7% |
| Retained Earnings | -$283.8M-12.2% | -$279.0M-11.2% | -$264.6M-7.0% | -$259.3M-6.5% | -$252.9M-492.4% | -$251.0M-7.7% | -$247.3M-8.7% | -$243.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
AKTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M+4.5% | -$2.5M-15.7% | -$3.0M-43.2% | -$2.1M-42.3% | -$3.3M+33.5% | -$2.1M+46.8% | -$2.1M+51.8% | -$1.5M+84.1% |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | $1K0.0% | $0 |
| Stock-Based Compensation | $711K-1.1% | $305K-70.0% | N/A | $685K+176.2% | $719K+61.6% | $1.0M+242.9% | N/A | $248K-18.7% |
| Financing Cash Flow | $8.0M+137.7% | $53K-97.5% | $5.8M+167.4% | $1.9M+528.2% | $3.4M | $2.1M+40.9% | $2.2M-38.8% | -$443K-130.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
AKTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -25.9%-18.4pp | -100.5%-83.5pp | N/A | -28.2% | -7.4% | -17.0% | N/A | N/A |
| Return on Assets | -12.4%-8.7pp | -42.6%-35.4pp | N/A | -14.1%+91.8pp | -3.7% | -7.3%+193.5pp | N/A | -105.9% |
| Current Ratio | 0.60+0.4x | 0.27+0.1x | 0.44+0.3x | 0.19-0.1x | 0.19 | 0.16-0.3x | 0.15-0.8x | 0.29 |
| Debt-to-Equity | 1.08+0.1x | 1.360.0x | 0.69-0.6x | 1.00 | 0.99 | 1.34 | 1.27 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.44), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $16.6M | — |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $65.1M | — |
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $239.9M | 67/100 |
| Kezar Life Sciences, Inc. KZR | FY2025 | $0 | -$56.0M | N/A | $53.9M | — |
| Lixte Biotechnology Holdings, Inc. LIXT | FY2025 | N/A | -$6.1M | N/A | $125.4M | — |
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $13.8M | — |
Where Akari Therapeutics plc Ranks
Frequently Asked Questions
Is Akari Therapeutics plc profitable?
No, Akari Therapeutics plc (AKTX) reported a net income of -$17.3M in fiscal year 2025.
What is Akari Therapeutics plc's return on equity (ROE)?
Akari Therapeutics plc (AKTX) has a return on equity of -61.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Akari Therapeutics plc's operating cash flow?
Akari Therapeutics plc (AKTX) recorded an outflow of $10.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Akari Therapeutics plc's total assets?
Akari Therapeutics plc (AKTX) had $47.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Akari Therapeutics plc spend on research and development?
Akari Therapeutics plc (AKTX) invested $2.8M in research and development during fiscal year 2025.
What is Akari Therapeutics plc's current ratio?
Akari Therapeutics plc (AKTX) had a current ratio of 0.44 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Akari Therapeutics plc's debt-to-equity ratio?
Akari Therapeutics plc (AKTX) had a debt-to-equity ratio of 0.69 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Akari Therapeutics plc's return on assets (ROA)?
Akari Therapeutics plc (AKTX) had a return on assets of -36.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Akari Therapeutics plc's P/E ratio?
Akari Therapeutics plc (AKTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $16.6M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Akari Therapeutics plc's price-to-sales ratio?
Akari Therapeutics plc (AKTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $16.6M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Akari Therapeutics plc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Akari Therapeutics plc (AKTX) held $5.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.6M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Akari Therapeutics plc's Piotroski F-Score?
Akari Therapeutics plc (AKTX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Akari Therapeutics plc's earnings high quality?
Akari Therapeutics plc (AKTX) reported a net loss of $17.3M while operations used $10.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Akari Therapeutics plc cover its interest payments?
Akari Therapeutics plc (AKTX) reported an operating loss of $17.3M against $100K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.